Boai NKY Pharmaceuticals Ltd (SHE:300109) — Market Cap & Net Worth
Market Cap & Net Worth: Boai NKY Pharmaceuticals Ltd (300109)
Boai NKY Pharmaceuticals Ltd (SHE:300109) has a market capitalization of $897.61 Million (CN¥6.13 Billion) as of August 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #9262 globally and #2286 in its home market, demonstrating a -5.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Boai NKY Pharmaceuticals Ltd's stock price CN¥12.69 by its total outstanding shares 483380605 (483.38 Million). See how much does Boai NKY Pharmaceuticals Ltd reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
Boai NKY Pharmaceuticals Ltd Market Cap History: 2015 to 2026
Boai NKY Pharmaceuticals Ltd's market capitalization history from 2015 to 2026. Data shows change from $4.98 Billion to $897.61 Million (-9.46% CAGR).
Boai NKY Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Boai NKY Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.01x
Boai NKY Pharmaceuticals Ltd's market cap is 1.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.25x
Boai NKY Pharmaceuticals Ltd's market cap is 6.25 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.35 Billion | $400.62 Million | $80.04 Million | 5.86x | 29.31x |
| 2017 | $2.24 Billion | $488.58 Million | $92.82 Million | 4.58x | 24.09x |
| 2018 | $863.14 Million | $698.28 Million | $89.55 Million | 1.24x | 9.64x |
| 2019 | $1.03 Billion | $924.43 Million | $122.80 Million | 1.12x | 8.40x |
| 2020 | $863.99 Million | $978.53 Million | $44.57 Million | 0.88x | 19.38x |
| 2021 | $1.38 Billion | $1.22 Billion | $207.05 Million | 1.13x | 6.65x |
| 2022 | $1.56 Billion | $1.49 Billion | $291.46 Million | 1.05x | 5.36x |
| 2023 | $1.18 Billion | $1.58 Billion | $493.03 Million | 0.74x | 2.39x |
| 2024 | $1.13 Billion | $1.61 Billion | $349.68 Million | 0.70x | 3.23x |
| 2025 | $1.19 Billion | $1.18 Billion | $190.09 Million | 1.01x | 6.25x |
Competitor Companies of 300109 by Market Capitalization
Companies near Boai NKY Pharmaceuticals Ltd in the global market cap rankings as of August 5, 2026.
Key companies related to Boai NKY Pharmaceuticals Ltd by market ranking:
- Linde plc Ordinary Shares (NASDAQ:LIN): Ranked #95 globally with a market cap of $210.18 Billion USD.
- AIR LIQUIDE ADR 1/5/EO 11 (F:AILA): Ranked #237 globally with a market cap of $103.86 Billion USD ( €88.84 Billion EUR).
- Air Liquide SA (PA:AI): Ranked #249 globally with a market cap of $101.06 Billion USD ( €86.44 Billion EUR).
- Sherwin-Williams Co (NYSE:SHW): Ranked #299 globally with a market cap of $87.81 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #95 | Linde plc Ordinary Shares | NASDAQ:LIN | $210.18 Billion | $480.46 |
| #237 | AIR LIQUIDE ADR 1/5/EO 11 | F:AILA | $103.86 Billion | €36.60 |
| #249 | Air Liquide SA | PA:AI | $101.06 Billion | €170.32 |
| #299 | Sherwin-Williams Co | NYSE:SHW | $87.81 Billion | $354.22 |
Boai NKY Pharmaceuticals Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Boai NKY Pharmaceuticals Ltd's market cap moved from $4.98 Billion to $ 897.61 Million, with a yearly change of -9.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥897.61 Million | -24.42% |
| 2025 | CN¥1.19 Billion | +5.27% |
| 2024 | CN¥1.13 Billion | -4.34% |
| 2023 | CN¥1.18 Billion | -24.54% |
| 2022 | CN¥1.56 Billion | +13.57% |
| 2021 | CN¥1.38 Billion | +59.27% |
| 2020 | CN¥863.99 Million | -16.24% |
| 2019 | CN¥1.03 Billion | +19.50% |
| 2018 | CN¥863.14 Million | -61.39% |
| 2017 | CN¥2.24 Billion | -4.69% |
| 2016 | CN¥2.35 Billion | -52.93% |
| 2015 | CN¥4.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Boai NKY Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $897.61 Million USD |
| MoneyControl | $897.61 Million USD |
| MarketWatch | $897.61 Million USD |
| marketcap.company | $897.61 Million USD |
| Reuters | $897.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Boai NKY Pharmaceuticals Ltd
Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP), Orarez, and in vitro diagnostic products, as well as invests in tumor drugs. It offers its products for pharmaceutical products, such as APIs and excipients; personal care products, including cosmetics, haircare, or… Read more